BIOMIND LABS INC. (3XI) - Total Liabilities

Latest as of September 2025: €1.62 Million EUR ≈ $1.89 Million USD

Based on the latest financial reports, BIOMIND LABS INC. (3XI) has total liabilities worth €1.62 Million EUR (≈ $1.89 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 3XI current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

BIOMIND LABS INC. - Total Liabilities Trend (2021–2024)

This chart illustrates how BIOMIND LABS INC.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BIOMIND LABS INC. assets under control.

BIOMIND LABS INC. Competitors by Total Liabilities

The table below lists competitors of BIOMIND LABS INC. ranked by their total liabilities.

Company	Country	Total Liabilities
Bluelinea SA PA:ALBLU	France	€8.79 Million
Axilion Smart Mobility Ltd TA:AILN	Israel	ILA1.41 Million
Madhucon Projects Limited NSE:MADHUCON	India	Rs55.76 Billion
Grand Gulf Energy Ltd AU:GGE	Australia	AU$706.41K
N2OFF Inc NASDAQ:NITO	USA	$4.67 Million
Expion360 Inc NASDAQ:XPON	USA	$1.32 Million
WestKam Gold Corp V:WKG	Canada	CA$880.07K

Liability Composition Analysis (2021–2024)

This chart breaks down BIOMIND LABS INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of BIOMIND LABS INC. to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.04	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.04	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	28.03	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BIOMIND LABS INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BIOMIND LABS INC. (2021–2024)

The table below shows the annual total liabilities of BIOMIND LABS INC. from 2021 to 2024.

Year	Total Liabilities	Change
2024-12-31	€1.34 Million ≈ $1.57 Million	-10.95%
2023-12-31	€1.51 Million ≈ $1.76 Million	+347.35%
2022-12-31	€336.72K ≈ $393.66K	+0.53%
2021-12-31	€334.95K ≈ $391.60K	--

About BIOMIND LABS INC.

F:3XI Germany Biotechnology

Market Cap

$3.31 Million

€2.83 Million EUR

Market Cap Rank

#29400 Global

#2540 in Germany

Share Price

€0.04

Change (1 day)

+0.00%

52-Week Range

€0.04 - €0.20

All Time High

€1.25